Clinical Trial Update: Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Parsaclisib for warm autoimmune hemolytic anemia was terminated, and efficacy and safety results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• Parsaclisib (parsaclisib)

Snippet

Sponsor: Incyte Corporation | Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 3 | Status: TERMINATED | Results posted: 2025-01-15